Recommend Cancer Biology & Therapy to your librarian for 2008. Download the form here.

Sign up for Table of Contents Alerts.

home subscribe search archive forthcoming

Email this page Print this page

Research Paper

In Vivo Studies of Pharmacokinetics and Efficacy of Bismuth-213 Labeled Antimelanoma Monoclonal Antibody 9.2.27

Syed M. Abbas Rizvi, Chang Fa Qu, Yan Jun Song, Chand Raja and Barry J. Allen

volume 4 | issue 7

july 2005
Pages: 763-768

We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:

 Download PDF

If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.

Objectives Key objectives of the study were to determine the pharmacokinetics and efficacy of the alpha emitting Bismuth- 213 labeled 9.2.27 alpha-immunoconjugate (AIC). Methods Balb/c nude mice were injected with varying doses of AIC to determine the pharmacokinetics of the AIC. The results were normalized to percent counts per minute (CPM) per gram per 3.7 MBq of the AIC (%CPM/g/3.7MBq) for each organ. Efficacy was determined by injected varying doses of AIC to different stages of tumour growth for intra-lesional, systemic and multiple dose TAT. Results Biodistribution studies showed similar pharmacokinetics for blood and brain, liver, kidneys, spleen, gut, heart, lungs and bone marrow, indicating that there was no retention of AIC. This is particularly important for brain (due to the presence of NG2+ cells) as the antibody 9.2.27 may reach NG2 positive cells. Tumour growth at 2-days post-inoculation was completely inhibited by TAT. The response to TAT was inversely proportional to tumour growth, i.e. a reduction in response was observed with increased tumour burden. A multiple dose regime was found to be more effective than single dose. Conclusions TAT is effective for the treatment of micrometastatic melanoma, when the tumour is preangiogenic in the form of isolated cells or cell clusters. There is no evidence of retention of AIC in brain, kidneys and other vital organs.




We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:

 Download PDF

If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.